Sellas Life Sciences Shares Slipped Amid Pipeline Updates
The company prepares to present new preclinical findings while continuing its ongoing clinical study in blood cancer.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Is now a good time for individual investors to base trades on speculative pharmaceutical clinical trials?
Sellas Life Sciences shares have declined 14% over the past month following recent overnight trading activity. The company is currently conducting a Phase 2 study for blood cancer while preparing to share new research on potential treatments for pancreatic cancer.
Why it matters
Investors and those following pancreatic cancer research are monitoring the company as it shifts focus toward upcoming preclinical findings. These updates provide early insights into how experimental therapies may eventually influence future treatment options for patients.
The Regal study has recorded 78 of 80 prespecified events, moving the trial closer to completion. Findings from this Phase 2 study are expected to be reported in the fourth quarter of 2026.
The players
Sellas Life Sciences
A clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies and therapies for blood cancers.
University of Wisconsin-Madison
A public research institution collaborating on preclinical studies regarding the use of SLS009 in pancreatic cancer models.
The details
Sellas Life Sciences is investigating the experimental therapy SLS009. Researchers from the University of Wisconsin-Madison are collaborating on preclinical studies to evaluate how this therapy performs in pancreatic cancer models. The company intends to lock its data, perform a full analysis, and unblind the trial results once the study reaches its 80-event threshold.
Timeline
August 2026: AML patient enrollment status was reported.
September 24, 2026: SLS stock slipped overnight.
September 25-28, 2026: The AACR Conference on Pancreatic Cancer takes place in San Diego.
Q4 2026: Topline results for the AML study are expected.
Health Landscape
The development of novel agents like SLS009 occurs within an evolving landscape of targeted therapies for solid and blood-based malignancies. These preclinical presentations mark a significant step toward defining the future scope of pancreatic cancer research.
As these studies remain in the preclinical or early clinical phase, they do not yet impact current standards of care. Patients interested in these experimental options should speak with their oncologist to determine if ongoing clinical trials are relevant to their specific diagnosis.
The takeaway
The research into SLS009 highlights the ongoing efforts to identify new treatment pathways for both pancreatic and blood cancers. Patients and caregivers should continue to monitor updates from clinical trial registries to track the progress of experimental therapies in their specific disease areas.
What happens next
Sellas Life Sciences expects to release topline results for its Phase 2 AML study during the fourth quarter of 2026.
Further reading
You can find more background on the current state of oncology research at our Cancer section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Is now a good time for individual investors to base trades on speculative pharmaceutical clinical trials?
